FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

2 Medical Device Benefit/Risk Guidances

[ Price : $8.95]

FDA issues two final guidances explaining its views on making benefit/risk determinations for certain medical device approval appl...

8 Observations on Dr. Reddys FDA-483

[ Price : $8.95]

FDA issues an FDA-483 with eight observations from an inspection at Dr. Reddys drug manufacturing facility in Andhra, Pradesh, Ind...

Tourettes Drug Gains Fast Track Status

[ Price : $8.95]

FDA grants Emalex Biosciences a fast track designation for its investigational drug ecopipam for treating patients with Tourette S...

OPDP Electronic Submission Webinar

[ Price : $8.95]

A CDER Office of Prescription Drug Promotion Webinar discusses contents of a recent guidance on providing promotional labeling and...

Submissions Extended for Quality Metrics Feedback

[ Price : $8.95]

Federal Register notice: FDA extends the submission period related to a 6/29 notice on its drug Quality metrics feedback program.

Guide on Cancer Trial Placebo Use & Blinding

[ Price : $8.95]

Federal Register notice: FDA releases a final guidance on using placebos and allowing blinding in cancer clinical trials.

AstraZeneca Study Meets Endpoint with Lupus Drug

[ Price : $8.95]

AstraZeneca says that the Phase 3 TULIP 2 trial for anifrolumab, an investigational drug for treating systemic lupus erythematosus...

Support, Criticism for Opioid Benefit/Risk Framework Guidance

[ Price : $8.95]

Stakeholders praise and criticize an FDA draft guidance on a benefit/risk assessment framewok for opioids.

FAERS Public Workshop Report

[ Price : $8.95]

FDA explains new requirements that are part of an upcoming switch to FAERS II that uses changes agreed to in an International Coun...

Agency Execs Defend Expedited Pathways

[ Price : $8.95]

CDER director Janet Woodcock and CBER director Peter Marks use an FDA Voices post to defend increases in the use of five congressi...